 epirubicin dose level prednisolon treatment advanc breast cancer result random trial eleven patient advanc breast cancer epirubicin prednisolon lep prednisolon hep intend treatment cours lep cours hep interv reason treatment progress diseas stabl diseas symptomat improv sever toxic intoler patient physician toxic respons interv world health organ who criteria respons toxic hundr patient elig analysi year patient lep hep significantli myelosuppress alopecia nausea vomit mucos high-dos arm equal patient lep arm treatment fourth cours hep arm reason stop progress diseas similar median number cours arm respons hep arm hep complet respons CR partial respons PR lep CR PR signific differ overal surviv progression-fre interv median surviv hep lep week